Published time: 04 May 2020
Authors: Ayşegül Ünüvar
Keywords: COVID-19, Coagulopathy, prophylaxis, treatment
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19. The lungs are the target organ for COVID-19; acute lung injury can progress to respiratory failure, and multiorgan failure can also occur. COVID-19 may predispose to both venous and arterial thromboembolic disease due to coagulation activation caused by a combination of excessive inflammation, platelet activation, endothelial dysfunction, and stasis in blood flow. This review was prepared in the light of the current information available in the first months of the COVID-19 pandemic. However, the existing evidence, including studies on thrombotic complications, is very limited and derived primarily from small and retrospective analyses, and more strong and high quality new studies are required.
COVID-19 ve Koagülopati
Leave a Comment